|
|
|
| Association between the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio and hyperuricemia among middle-aged and elderly population of different genders |
| LIANG Chunduo1,2, YANG Hujia1, HUANG Xiaofeng1, MA Junqian1, DENG Shusong1
|
1. School of Public Health, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China;
2. Baise Center for Disease Control and Prevention, Baise, Guangxi 533000, China |
|
|
|
|
Abstract Objective To explore the association between the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio (hs-CRP/HDL-C) and hyperuricemia among middle-aged and elderly population by gender, so as to provide the evidence for hyperuricemia prevention and control in the middle-aged and elderly population. Methods Based on the 2015 survey data from the China Health and Retirement Longitudinal Study (CHARLS), data including demographic characteristics, lifestyles, disease histories, serum uric acid, hs-CRP and HDL-C were collected for participants aged ≥45 years, and the hs-CRP/HDL-C ratio was calculated. Multivariable logistic regression models were used to analyze the association between hs-CRP/HDL-C and hyperuricemia stratified by gender, and restricted cubic spline models were applied to assess the dose-response relationships. Results A total of 9 990 middle-aged and elderly participants were included, including 4 674 males (46.79%) and 5 316 females (53.21%). There were 1 092 cases of hyperuricemia with prevalence of 10.93%, including 614 male cases (prevalence 13.14%) and 478 female cases (prevalence 8.99%). After adjusting for covariable including age, education level and marital status, multivariable logistic regression analysis showed that hs-CRP/HDL-C was significantly associated with hyperuricemia risk in both males (OR=1.660, 95%CI: 1.400-1.968) and females (OR=2.190, 95%CI: 1.803-2.659). Restricted cubic spline analysis showed a non-linear relationship between hs-CRP/HDL-C and hyperuricemia risk for both genders (both Pfor non-linearity<0.05). Conclusion An elevated hs-CRP/HDL-C may increase the risk of hyperuricemia in middle-aged and elderly population of both genders, with a relatively higher risk observed in females.
|
|
Received: 21 January 2026
Revised: 23 April 2026
Published: 27 July 2026
|
|
|
|
|
|
[1] Johnson R,Gruev I,Yotov Y,et al.Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk:2025 update[J/OL].Eur J Intern Med,2026,146[2026-04-23].https://doi.org/10.1016/j.ejim.2026.106727.
[2] Zhang M,Zhu X,Wu J,et al.Prevalence of hyperuricemia among Chinese adults:findings from two nationally representative cross-sectional surveys in 2015-2016 and 2018-2019[J/OL].Front Immunol,2022,12[2026-04-23].https://doi.org/10.3389/fimmu.2021.791983.
[3] Paduraru L,Vesa C,Popoviciu M S,et al.Common pathophysiological mechanisms connecting dyslipidemia and hyperuricemia:a narrative review[J].Maedica,2025,20(3):591-599.
[4] Rahali F Z,Mimouni N,Boukhira A,et al.The clinical utility of standard and high-sensitivity C-reactive protein:a narrative review[J/OL].SN Compr Clin Med,2024,6(1)[2026-04-23].https://doi.org/10.1007/s42399-024-01693-3.
[5] Grao-Cruces E,Lopez-Enriquez S,Martin M E,et al.High-density lipoproteins and immune response:a review[J].Int J Biol Macromol,2022,195:117-123.
[6] Sun H H,Yang J Z,Ma L,et al.Association between hs-CRP/HDL-C ratio and risk of prediabetes or diabetes:a cross-sectional study based on NHANES2015-2023[J/OL].BMC Endocr Disord,2025,25(1)[2026-04-23].https://doi.org/10.1186/s12902-025-02004-0.
[7] Li J Y,Ma H.Associations of the hs-CRP/HDL-C ratio with cardiovascular disease among US adults:evidence from NHANES 2015-2018[J/OL].Nutr Metab Cardiovasc Dis,2025,35(4)[2026-04-23].https://doi.org/10.1016/j.numecd.2024.103814.
[8] Chen X X,Crimmins E,Hu P P,et al.Venous blood-based biomarkers in the China health and retirement longitudinal study:rationale,design,and results from the 2015 wave[J].Am J Epidemiol,2019,188(11):1871-1877.
[9] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.
[10] Wei J F,Guo J H,Yin X L,et al.Correlation of the lipid complex marker hs-CRP/HDL-C ratio with hyperuricaemia:a cross-sectional retrospective study from NHANES2015-2018[J/OL].Sci Rep,2025,15(1)[2026-04-23].https://doi.org/10.1038/s41598-024-83126-8.
[11] Huang D N,Ma J,Zhao Y,et al.Higher C-reactive protein to high-density lipoprotein cholesterol ratio is associated with hyperuricemia in diabetes and prediabetes:a cross-sectional study[J/OL].Front Endocrinol,2025,16[2026-04-23].https://doi.org/10.3389/fendo.2025.1619370.
[12] Tian J,Huang Y M,Xiao Z,et al.The association between the uric acid to high-density lipoprotein cholesterol ratio (UHR) index and obesity in postmenopausal women:a cross-sectional analysis based on the NHANES[J/OL].Lipds Heal Dis,2025,24(1)[2026-04-23].https://doi.org/10.1186/s12944-025-02715-2.
[13] SenthilKumar G,Katunaric B,Bordas-Murphy H,et al.Estrogen and the vascular endothelium:the unanswered questions[J/OL].Endocrinology,2023,164(6)[2026-04-23].https://doi.org/10.1210/endocr/bqad079.
[14] Di Petrillo A,Fais A,Raho N,et al.Xanthine oxidase-dependent activation of NLPR3 inflammasome in epithelial cells sustains inflammation in inflammatory bowel disease[J].Inflamm Bowel Dis,2025,31(12):3398-3406.
[15] Yang Q Q,Xu Y D,Zhang J,et al.From soluble uric acid to sodium urate crystal:immune metabolic inflammation driven by uric acid morphological transformation and mechanism-oriented therapy[J/OL].Front Immunol,2026,17[2026-04-23].https://doi.org/10.3389/fimmu.2026.1794782.
[16] Ito F,Sono Y,Ito T.Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress:oxidative stress in diabetes,atherosclerosis,and chronic inflammation[J/OL].Antioxidants(Basel),2019,8(3)[2026-04-23].https://doi.org/10.3390/antiox8030072.
[17] Qian F Q,Hong Z,Wei J H,et al.Association between the serum uric acid-to-high-density lipoprotein cholesterol ratio and microalbuminuria in individuals with type 2 diabetes mellitus[J/OL].Eur J Med Res,2025,30(1)[2026-04-23].https://doi.org/10.1186/s40001-025-03465-8. |
|
|
|
